HNSCC tumors express elevated levels of the epidermal growth factor receptor (EGFR), which has prompted the extensive clinical investigation of EGFR inhibitors, primarily monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs). Here, EGFR is linked to head and neck squamous cell carcinoma.